SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 25.65+2.7%Jan 30 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: John Romeo who wrote (11281)8/17/1999 1:11:00 AM
From: Cacaito  Read Replies (1) of 17367
 
This drug either show decrease mortality or bust.

Morbidity is the reason for the 90 days follow up period.

Lost of limbs (amputations)is one of the sequelae, and neurologic outcome (brain damage or not, severe or less) is the one to follow patient for longer period.

But forget morbidity, they have to show clear decrease in mortality.

FDA wants more detail? FDA always wants more detail, they are practically breathing inside this type of trials.

This looks like Cephalon/Myothrophin, or worse E5.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News